How Stem Cell Therapy Changes With Age
Age alters stem cell number, potency and niche signalling. This page reviews what the registered trial and preclinical literature records about stem cell therapy across age-related conditions, including where evidence re
What the question means in laboratory terms
Stem cell therapy is the administration of stem or progenitor cells, or of cells genetically modified at a stem cell stage, for a research or clinical purpose. The category includes mesenchymal stem/stromal cells (MSCs), autologous haematopoietic stem and progenitor cells (HSPCs), and neural crest-derived stem cells. The evidence base below does not supply a single sequence, formula or molecular weight for the class, because the class is defined by cell phenotype and source rather than by a chemical identifier. What the evidence does supply is trial registration data: a Phase II trial of MSC therapy in non-viral acute-on-chronic liver failure (ACLF) [1]; a Phase IIb single-arm study of autologous HSPCs transduced with the GLOBE lentiviral vector in transfusion-dependent beta-thalassaemia [2]; a trial of pulsed electromagnetic field (PEMF) therapy in knee osteoarthritis, a condition in which stem cell therapy is also being developed [3]; and a study of autologous MSC therapy in premature ovarian failure (POF) [4].
The work centres on mesenchymal and haematopoietic stem cell populations and their regenerative signalling, with mitochondrial oxidative phosphorylation (OXPHOS) identified as a determinant of MSC functional fate in three-dimensional spheroid culture [5].
Research Studies
MSC therapy and non-viral acute-on-chronic liver failure
Liver disease deaths are rising while transplant availability remains limited. In India, more than 100,000 transplants are needed annually and only about 2,500 are performed, so non-transplant options are being sought. Regenerative therapy with MSCs has shown promise but lacks validation, particularly for non-viral ACLF. A proposed National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM) Phase II trial is designed to develop and validate MSC-based therapy to promote native liver regeneration and to offer a transplant-free treatment option [1]. The trial is registered but the evidence block does not report enrolment, dosing, or outcomes; the finding recorded here is the stated rationale and design, not a demonstrated effect.
Gene-modified HSPC therapy and transfusion-dependent beta-thalassaemia
In transfusion-dependent beta-thalassaemia, a prospective, dual-centre, single-dose, Phase IIb, single-arm, open-label study is planned. It involves a single infusion of autologous HSPCs genetically modified with the GLOBE lentiviral vector, using an improved transduction protocol, in 9 patients. Four study phases are foreseen, beginning with screening to assess inclusion and exclusion criteria after informed consent, with recruitment from two participating sites including IRCCS Ospedale San Raffaele [2]. The evidence block reports the protocol and the planned population; it does not report efficacy results.
PEMF and knee osteoarthritis in an ageing population
Health care costs are increasing, with a projected economic burden on ageing societies such as Hong Kong. Degenerative musculoskeletal disorders including osteoarthritis present a major challenge: more than 40% of elderly people are reported to suffer from knee OA. OA is a debilitating progressive disease with symptoms such as acute pain causing loss of mobility, and there is currently no cure. Pharmacological treatment and regenerative technologies such as stem cell therapy are being actively developed, but most options are expensive and side effects are not uncommon; cost-effectiveness is also a major consideration [3]. This trial concerns PEMF rather than a cell product, and it is included here because it defines the clinical and economic context in which stem cell approaches to age-related joint disease are being assessed.
Autologous MSC therapy and premature ovarian failure
A registered study evaluates the therapeutic potential of autologous MSC therapy in women suffering from premature ovarian failure [4]. The evidence block states the purpose of the work and the population; it does not report a mechanism, a dose, or an outcome. No claim about restoration of ovarian function is supported by the material provided.
Mitochondrial modulation and MSC spheroid metabolism in bone regeneration
Mitochondrial OXPHOS plays a crucial role in determining the functional fate of MSCs, but strategies to precisely modulate mitochondrial bioenergetics within three-dimensional MSC spheroids to improve bone repair remain limited. A study reports a mitochondrial-targeted nano-enhancer driving a self-amplifying NAD+ feedback loop to reprogram MSC spheroid metabolism for accelerated bone regeneration [5]. This is preclinical work; the finding concerns cultured MSC spheroids and bone repair in an experimental model, not a human outcome.
Hair follicle-derived neural crest stem cells and hearing loss in a rat model
Stem cell therapy has been explored for sensorineural hearing loss (SNHL), but effective cell delivery remains a critical challenge. In an ouabain-induced spiral ganglion neuron injury model, a study reports partial hearing recovery after cochlear nerve surface transplantation of hair follicle-derived neural crest stem cells in a rat model of neural hearing loss [6]. The observation is animal-only and concerns a specific delivery route; it does not establish an effect in humans.
Adipose-derived stem cells and erectile function in a rat model
Erectile dysfunction following non-nerve-sparing prostatectomy is prevalent. Although adipose-derived stem cells (ASCs) have shown therapeutic potential for erectile dysfunction, the underlying mechanisms remain unclear. A study investigated the therapeutic effects of exogenous stem cells and their recruitment of endogenous stem cells in a rat model of cavernous nerve injury, reporting restoration of erectile function and promotion of endogenous stem cell recruitment [7]. This is animal-only evidence.
What changes with age across these models
The evidence block does not contain a controlled comparison of stem cell therapy in young versus aged subjects. What it does contain is a set of conditions whose incidence or burden is concentrated in older populations, and a set of preclinical findings in which the metabolic state of the transplanted or cultured cell population is treated as a variable. The table below summarises the age-related context recorded in each source.
| Source | Cell or intervention | Population or model | Age-related context recorded |
|---|---|---|---|
| [1] | MSCs | Non-viral ACLF patients (Phase II) | Rising liver disease deaths; transplant scarcity |
| [2] | Autologous HSPCs, GLOBE lentiviral vector | Transfusion-dependent beta-thalassaemia, 9 patients (Phase IIb) | Not specified in the evidence block |
| [3] | PEMF (context: stem cell therapy also in development) | Knee OA patients | >40% prevalence in the elderly |
| [4] | Autologous MSCs | Women with premature ovarian failure | Condition defined by premature loss of function |
| [5] | Mitochondrial-targeted nano-enhancer in MSC spheroids | Preclinical bone regeneration | OXPHOS as determinant of MSC fate |
| [6] | Hair follicle-derived neural crest stem cells | Rat ouabain-induced SGN injury | Animal-only |
| [7] | Adipose-derived stem cells | Rat cavernous nerve injury | Animal-only |
Where the evidence is animal-only or in vitro
Two of the sources above are animal-only: the rat cochlear nerve transplantation study [6] and the rat cavernous nerve injury study [7]. One is in vitro or ex vivo in its central claim: the MSC spheroid metabolic reprogramming work [5]. The registered trials [1][2][3][4] report design, rationale and population, not results. No source in the evidence block reports a completed comparison of stem cell therapy outcomes stratified by recipient age, and no source reports a human dose. Any statement that a given stem cell preparation behaves differently in older recipients would require evidence not present here.
If you are reading this for personal health reasons
The materials described on this page are supplied for laboratory research use only. We do not provide dosing information, medical guidance, or recommendations for any compound or cell product in humans. Anyone considering a stem cell or regenerative treatment for themselves should speak to a licensed clinician.
Sources
- [1] National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Evaluating Mesenchymal Stem Cell Therapy in Non-viral Acute on Chronic Liver Failure (ACLF) Patient- Phase-II Trial. https://clinicaltrials.gov/study/NCT07131306
- [2] Gene-Modified Stem Cell Therapy for Subjects With Transfusion-dependent Beta-thalassemia. https://clinicaltrials.gov/study/NCT07680803
- [3] The Effect of PEMF for Patients With Knee OA. https://clinicaltrials.gov/study/NCT05548712
- [4] "It is a Real" The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure. https://clinicaltrials.gov/study/NCT02372474
- [5] Mitochondrial-targeted nano-enhancer driving a self-amplifying NAD+ feedback loop to reprogram MSC spheroids metabolism for accelerated bone regeneration. https://pubmed.ncbi.nlm.nih.gov/42497772/
- [6] Partial hearing recovery after cochlear nerve surface transplantation of hair follicle-derived neural crest stem cells in neural hearing loss rat. https://europepmc.org/article/PMC/PMC13394508
- [7] Adipose-derived stem cell therapy restores erectile function and promotes endogenous stem cell recruitment in a rat model of cavernous nerve injury. https://pubmed.ncbi.nlm.nih.gov/40954197/